Table 2 The CDR3 regions of the top 5 TCRs from each group.
From: Artificial intelligence-powered discovery of small molecules inhibiting CTLA-4 in cancer
Sample | % of total TCRs | TCR β | TCR α |
|---|---|---|---|
7.7% | CASSHDWGDNYAEQFF | CAMREMDYNQGKLIF, CAMREMDYNQGKLIF, CAVKGFASALTF | |
4.1% | CASSQGLGEDTQYF | CAAKDYSNNRLTL | |
PBS | 1.8% | CASSQEMGTGGREGTQYF | CAVSMSGSFNKLTF |
1.4% | CASSQTQGADTQYF | CAARDYSNNRLTL | |
0.9% | CASSFPGSSYEQYF | CAASSNNNNAPRF | |
11.3% | CASRTGDNYAEQFF | CAVSDGSGYNKLTF | |
7.2% | CASARTGGYEQYF, CASSEGTGGTPNSDYTF | CALSDQGGSAKLIF | |
Anti-PD-1 | 5.9% | CASSLELGGLEQYF | CAVTPDYSNNRLTL |
4.3% | CAWSQQGRAEQFF, CGARDVGLGVPEQFF | CAAEEESNNRIFF, CVLGLNNAGAKLTF | |
2.7% | CASSLAGGSQNTLYF | CAVSAKNNAGAKLTF | |
4.8% | CASSQEGDGERLFF | CAVSMTNTNKVVF, CAVSTENSGGSNAKLTF | |
1.9% | CASSPGTGGYEQYF | CASNTGYQNFYF | |
Ipilimumab | 1.6% | CASSQDIGWGVYAEQFF | CALVADSNYQLIW |
1.3% | CASSLELGGPEQYF | CAASDYSNNRLTL | |
0.6% | CASSPQGAGTGQLYF | CARGSNNRIFF, CAVSAGDYAQGLTF | |
5.7% | CASSQEGDGNTLYF | CALGENAPRF | |
4.3% | CASSLGDRDTQYF, CASSPGTGGGTGQLYF | CAGTNYNQGKLIF | |
D11 | 4.2% | CASSLAWGGGANERLFF, CASSLEGGRKEQYF | CATDTDYSNNRLTL |
3.0% | CASSLVGGRDTQYF | CAVSMGNTNKVVF | |
3.0% | CASGEPENTLYF | CAMREASSGSWQLIF | |
15.3% | CASRGTGGAWAEQFF | CALVDLTTASLGKLQF | |
8.8% | CASSPTGGGDTQYF | CAVTKDYSNNRLTL | |
D11+anti-PD-1 | 6.4% | CASSAPGGTETLYF | CALSDYSNNRLTL |
3.4% | CASSSGANSDYTF | CAMRELASSSFSKLVF | |
2.3% | CASSLQANQDTQYF | CAARANYGNEKITF |
